HC Wainwright Reaffirms Buy Rating for Perspective Therapeutics (NYSE:CATX)

Analysts at HC Wainwright have reaffirmed their "buy" rating for Perspective Therapeutics (NYSE:CATX) in a report published on Monday. They set a target price of $10.00 for the stock. This price target implies a substantial potential upside of approximately 354.55% from the stock's current trading price.

Stories surrounding CATX have also appeared in various other financial reports. For instance, Royal Bank of Canada adjusted their price objective for Perspective Therapeutics from $16.00 to $15.00 while maintaining an "outperform" rating in a research note released recently. Furthermore, Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in their research on March 6. On March 7, Scotiabank initiated coverage of the company with a "sector outperform" rating, setting a price target of $15.00. Additionally, Cantor Fitzgerald enhanced their rating for Perspective Therapeutics to "strong-buy" in a report issued on March 4. Wedbush also reiterated an "outperform" rating, assigning a target price of $11.00 in their research note dated March 26. In total, there is a mix of ratings: one analyst has a hold rating, eight analysts have issued buy ratings, and three analysts have given it a strong buy rating. Data from MarketBeat.com shows the average rating for the stock is "buy" with an average target price of $14.44.

Stock Performance of Perspective Therapeutics

Pleasantly, the stock opened at $2.20 on Monday. The company's 50-day moving average stands at $2.94 with a two-hundred day moving average of $6.29. Over the past twelve months, the stock reached a low of $2.18 and a high of $19.05.

Institutional Investment in Perspective Therapeutics

Recent activity suggests interest from institutional investors in Perspective Therapeutics. Charles Schwab Investment Management Inc. increased its holdings in the stock by 221.7% during the third quarter, now owning 433,522 shares valued at $5,788,000 after acquiring an additional 298,778 shares last quarter. Likewise, State Street Corp boosted their stake in Perspective Therapeutics by 119.6%, bringing their total to 2,190,239 shares worth $29,240,000 following an acquisition of 1,192,812 shares. Janus Henderson Group PLC raised its holdings by 8.0% during the same period, now owning a total of 4,799,352 shares valued at $64,014,000 after purchasing an additional 355,685 shares. FMR LLC saw a significant increase by 3,994.9%, owning 5,504,822 shares valued at $73,489,000 after acquiring 5,370,392 shares. Lastly, BNP Paribas Financial Markets reported a massive increase in position by 1,302.7%, now holding 47,565 shares worth $635,000 after adding 44,174 shares. In total, institutional investors and hedge funds own approximately 54.66% of Perspective Therapeutics’ stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc., alongside its subsidiaries, works on developing precision-targeted alpha therapies (TAT) aimed at treating various types of cancer. Their initial programs include candidates such as VMT-a-NET, which is currently undergoing Phase 1/2a clinical trials for patients with unresectable or metastatic tumors expressing somatostatin receptor type 2 (SSTR2). This focuses on patients who have not yet had peptide-targeted radiopharmaceutical therapy. Another candidate, VMT01, is in Phase 1/2a clinical trials, targeting treatment for patients with progressive metastatic melanoma that test positive for the melanocortin 1 receptor (MC1R).

Further Reading

• Investing in Perspective Therapeutics: Opportunities and Risks
• Penny Stocks: Finding Solid Investment Options
• Exploring High-Performing Tech ETFs
• Understanding Special Dividends in the Market
• Analyzing Netflix's Position as a Safe Haven Stock
• Deciding When to Sell Stocks for Maximum Gain
• Lululemon's Market Moves: A Buying Opportunity?

stocks, rating, investment